Browsing by Author Schachter, Jacob

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
2015Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialLong, Georgina; Amonkar, Mayur M; Drucis, Kamil; Dummer, R; et al, Various; Grange, Florent; Grob, Jean Jacques; Karaszewska, Boguslawa; Mackiewicz, Andrzej; Schachter, Jacob; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreComparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial, The Lancet Oncology, vol.16, 13, 2015,pp 1389-1398
2013Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced MelanomaKefford, Richard (Rick); Chiarion-Sileni, Vanna; Eggermon, Alexander; et al, Various; Grob, Jean Jacques; Mackiewicz, Jacek; Mortier, Laurent; O'Day, Steven; Robert, Caroline; Schachter, Jacob; Testori, Alessandro; Western Clinical School: Westmead Millennium InstituteFinal Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma, Journal of Clinical Oncology, vol.31, 9, 2013,pp 1211-1218
2015Improved overall survival in melanoma with combined dabrafenib and trametinibLong, Georgina; Chiarion-Sileni, Vanna; Dummer, R; et al, Various; Grange, Florent; Karaszewska, Boguslawa; Lichinitser, Michael; Mackiewicz, Andrzej; Mortier, Laurent; Robert, Caroline; Rutkowski, Piotr; Schachter, Jacob; Stroiakovski, Daniel; Central Clinical School: The Sydney Cancer CentreImproved overall survival in melanoma with combined dabrafenib and trametinib, New England Journal of Medicine, vol.372, 1, 2015,pp 30-39
2017Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Carlino, Matteo; Long, Georgina; Arance, A; Daud, Adil; et al, Various; Grob, Jean Jacques; Larkin, James; Lotem, Michal; McNeil, Catriona M.; Mortier, Laurent; Ribas, Antoni; Schachter, Jacob; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicinePembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), The Lancet, vol.390, 10105, 2017,pp 1853-1862
2015Pembrolizumab versus ipilimumab in advanced melanomaCarlino, Matteo; Long, Georgina; Arance, Ana; Daud, Adil; et al, Various; Grob, Jean Jacques; Larkin, James; Lorigan, Paul; Lotem, Michal; McNeil, Catriona; Mortier, Laurent; Neyns, Bart; Robert, Caroline; Schachter, Jacob; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentrePembrolizumab versus ipilimumab in advanced melanoma, The New England Journal of Medicine, vol.372, 26, 2015,pp 2521-2532
2013Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaKefford, Richard (Rick); et al, Various; Garbe, Claus; Gogas, Helen; Haanen, John; Linette, Gerald; Lorigan, Paul; Marmol, Maribel; Marshall, Margaret A.; Punt, Cornelis J.A.; Ribas, Antoni; Schachter, Jacob; Western Clinical School: Westmead Millennium InstitutePhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, Journal of Clinical Oncology, vol.31, 5, 2013,pp 616-622
2017Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsLong, Georgina; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Garbe, Claus; Hauschild, Axel; Karaszewska, Boguslawa; Levchenko, Evgeny; Schachter, Jacob; Schadendorf, D; Stroiakovski, Daniel; Northern Clinical School: MedicineThree-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials, European Journal of Cancer, vol.82, N/A, 2017,pp 45-55